This in-depth examination of the healthcare and life sciences (HCLS) deal market explores how the major developments of 2024 have prepared the way for the year ahead. In this paper, we analyze how eight subsectors fared during another year of industry challenges and global instability, and how deal activity and market drivers could shape the 2025 investment landscape. The macroeconomic climate improved last year, seemingly setting the stage for a more productive HCLS M&A marketplace. With the hope of better economic conditions as well as reduced headwinds for many subsectors, respondents to KPMG’s survey said they are looking forward to increased M&A in 2025.
Read the full article: KPMG 2025 Healthcare & Life Sciences Investment Outlook //
Source: https://kpmg.com/us/en/articles/2025/kpmg-2025-healthcare-life-sciences-investment-outlook.html